Johnson & Johnson posts press release on MonumenTAL-6 multiple myeloma trial results
JNJ•MonumenTAL-6 phase 3 results in relapsed/refractory multiple myeloma
Johnson & Johnson posted a July 23, 2026 press release on Phase 3 MonumenTAL-6 results in relapsed/refractory multiple myeloma.
- TECVAYLI + TALVEY cut risk of disease progression or death by 89% (HR 0.11), risk of death by 62% (HR 0.38).
- TALVEY + pomalidomide reduced risk of progression or death by 73% (HR 0.27) versus standard of care.
- The IDMC recommended unblinding at the first interim analysis; results are to be presented at a future medical meeting.
Related News
Honeywell Technologies CEO Expects Divestitures Of Productivity Solution And Services, Warehouse And Workforce Solution Business By Early August 2026 - Conf. Call
HON•
Greenland Mines director Jason Sawyer reports purchase of 240,000 common shares for $55,944
GRML•
